Spots Global Cancer Trial Database for Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer

Official Title: Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: a Phase II Study.

Study ID: NCT02745639

Conditions

Rectal Neoplasms

Interventions

VMAT-SIB

XELOX

Study Description

Brief Summary: This was a prospective phase II study on patients with locally advanced rectal cancer or local recurrence, to evaluate the pathological response and resectability of a neoadjuvant treatment based on the use of a combined treatment with VMAT-SIB and two drugs chemotherapy ( XELOX).

Detailed Description: This was a prospective phase II study on patients with LARC or local recurrence, to evaluate the pathological response and resectability of a neoadjuvant treatment based on the use of a combined treatment with VMAT-SIB and two drugs chemotherapy ( XELOX). The primary aim was to asses the pathological response rate. Key secondary aim was the acute toxicity. Secondary aims were local control, disease-free survival (DFS) and overall survival (OS). The follow-up period of each subjects started at the end of combined treatment and concluded after a period of maximum 60 months or until death.